The REMS program for the ERA drug class was established due to the risk of embryofetal toxicity seen from animal studies.

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

Endothelin (ET) is a 21-amino acid peptide that is produced by endothelial cells after processing from preproendothelin, its precursor molecule (Figure 1).

Schlaich said the endothelin pathway has been previously “implicated in the pathogenesis of hypertension,” particularly in sodium and water retention; the endothelin A and B receptors exert their ...

Endothelin, a chain of amino acids that is produced by endothelial and other cell types, can bind to these receptors on smooth muscle cells to control how much they constrict and dilate.

US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination ...

Macitentan demonstrated superiority over other endothelin receptor antagonists (ERAs) in the treatment of pulmonary arterial hypertension (PAH), according to findings from the first real-world ...